These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38994659)

  • 21. Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study.
    Grellmann C; Dombrowsky W; Fabricius V; Suruki R; Sheahan A; Joeres L
    Adv Ther; 2021 Jan; 38(1):366-385. PubMed ID: 33128201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
    Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
    Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
    Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
    Bonafede M; Johnson BH; Fox KM; Watson C; Gandra SR
    J Dermatolog Treat; 2013 Oct; 24(5):369-73. PubMed ID: 23441722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Hoit Marchlewicz E; Shrady G; Zhao Y; Mendelsohn AM
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects.
    Utama WS; Lestari W; Hajar S; Sylvawani M; Ismida FD; Akele RY
    Narra J; 2024 Apr; 4(1):e207. PubMed ID: 38798877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database.
    Merola JF; Patil D; Egana A; Steffens A; Webb NS; Gottlieb AB
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2635-2648. PubMed ID: 37726542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?
    Ball GD; Hamade H; Gottlieb AB; Kirby B; Duffin KC
    J Rheumatol; 2024 Oct; 51(Suppl 2):39-42. PubMed ID: 39089834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Armario-HIta JC; Martinez-Pilar L
    Int J Dermatol; 2020 May; 59(5):633-639. PubMed ID: 32173862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
    Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R
    Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
    Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?
    Löfvendahl S; Petersson IF; Theander E; Svensson Å; Zhou C; Steen Carlsson K
    J Rheumatol; 2016 Mar; 43(3):640-7. PubMed ID: 26773111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.